MXPA05007684A - Eteres fenoxicos de aminoacidos. - Google Patents
Eteres fenoxicos de aminoacidos.Info
- Publication number
- MXPA05007684A MXPA05007684A MXPA05007684A MXPA05007684A MXPA05007684A MX PA05007684 A MXPA05007684 A MX PA05007684A MX PA05007684 A MXPA05007684 A MX PA05007684A MX PA05007684 A MXPA05007684 A MX PA05007684A MX PA05007684 A MXPA05007684 A MX PA05007684A
- Authority
- MX
- Mexico
- Prior art keywords
- amino acid
- acid phenoxy
- phenoxy ethers
- ethers
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44077203P | 2003-01-17 | 2003-01-17 | |
| US10/356,113 US6794401B2 (en) | 2003-01-17 | 2003-01-31 | Amino acid phenoxy ethers |
| PCT/US2004/000790 WO2004066964A2 (en) | 2003-01-17 | 2004-01-13 | Amino acid phenoxy ethers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05007684A true MXPA05007684A (es) | 2006-03-10 |
Family
ID=32716922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05007684A MXPA05007684A (es) | 2003-01-17 | 2004-01-13 | Eteres fenoxicos de aminoacidos. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6794401B2 (enExample) |
| EP (1) | EP1583529B9 (enExample) |
| JP (1) | JP4833072B2 (enExample) |
| KR (1) | KR101085315B1 (enExample) |
| AT (1) | ATE532510T1 (enExample) |
| AU (1) | AU2004207449A1 (enExample) |
| BR (1) | BRPI0406772B1 (enExample) |
| CA (1) | CA2513496C (enExample) |
| CY (1) | CY1112673T1 (enExample) |
| DK (1) | DK1583529T3 (enExample) |
| EA (1) | EA200501078A1 (enExample) |
| ES (1) | ES2374724T3 (enExample) |
| MA (1) | MA27658A1 (enExample) |
| MX (1) | MXPA05007684A (enExample) |
| NO (1) | NO330984B1 (enExample) |
| NZ (1) | NZ541328A (enExample) |
| PT (1) | PT1583529E (enExample) |
| SI (1) | SI1583529T1 (enExample) |
| TW (1) | TWI325420B (enExample) |
| WO (1) | WO2004066964A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7781464B2 (en) * | 2003-01-17 | 2010-08-24 | Bexel Pharmaceuticals, Inc. | Heterocyclic diphenyl ethers |
| US7521465B2 (en) * | 2003-01-17 | 2009-04-21 | Bexel Pharmaceuticals, Inc. | Diphenyl ether derivatives |
| US7087576B2 (en) * | 2003-10-07 | 2006-08-08 | Bexel Pharmaceuticals, Inc. | Dipeptide phenyl ethers |
| US7592486B2 (en) * | 2004-09-16 | 2009-09-22 | Board Of Regents Of The University Of Nebraska | Anhydrous fluoride salts and reagents and methods for their production |
| JP2008533122A (ja) * | 2005-03-18 | 2008-08-21 | オーキッド ケミカルズ アンド ファーマシューティカルズ リミテッド | 新規なチロシン誘導体 |
| WO2007029062A2 (en) * | 2005-07-29 | 2007-03-15 | Orchid Research Laboratories Limited | Novel pyridine derivatives |
| US7989480B2 (en) | 2006-08-04 | 2011-08-02 | Decode Genetics Ehf | Aryl amino acid derivatives as inhibitors for treating inflammation |
| KR20100037047A (ko) * | 2007-06-26 | 2010-04-08 | 렉시컨 파마슈티컬스 인코퍼레이티드 | 세로토닌-매개 질환 및 장애의 치료 방법 |
| AU2008275179B2 (en) | 2007-07-11 | 2013-09-12 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
| WO2009030968A1 (en) * | 2007-09-05 | 2009-03-12 | Orchid Research Laboratories Limited | Mao a inhibitors with a diphenyl ether-substructure. |
| ATE536347T1 (de) | 2008-05-20 | 2011-12-15 | Merck Sharp & Dohme | Effiziente herstellung heterologer proteine unter verwendung von mannosyltransferaseinhibitoren |
| US20140187594A1 (en) | 2010-07-28 | 2014-07-03 | Orchid Chemicals And Pharmaceuticals Ltd | Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases |
| WO2012153775A1 (ja) | 2011-05-10 | 2012-11-15 | 国立大学法人神戸大学 | Ras機能阻害作用を有するチオキソチアゾリジン誘導体 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020049240A1 (en) * | 1994-12-19 | 2002-04-25 | Beecham Group P.1.C. | Novel compounds |
| US5166137A (en) * | 1991-03-27 | 1992-11-24 | Nobipols Forskningsstiftelse | Guluronic acid polymers and use of same for inhibition of cytokine production |
| US5441971A (en) * | 1991-04-11 | 1995-08-15 | The Upjohn Company | Thiazolidinedione derivatives, production and use thereof |
| ATE185564T1 (de) * | 1992-08-31 | 1999-10-15 | Sankyo Co | Oxazolidin-derivate mit antidiabetika und anti- fettleibigkeit-eigenschaften, ihre herstellung und therapeutische verwendung |
| TW268952B (enExample) * | 1993-02-26 | 1996-01-21 | Takeda Pharm Industry Co Ltd | |
| CA2171827C (en) * | 1993-09-15 | 2004-06-29 | Jerrold Olefsky | Use of thiazolidinediones to prevent or delay onset of niddm |
| US5527546A (en) * | 1994-08-10 | 1996-06-18 | Bayer Corporation | Human interleukin 6 inhibitor |
| DE4432101A1 (de) * | 1994-09-09 | 1996-03-14 | Hoechst Ag | Aminosäure-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| WO1996035782A1 (en) * | 1995-05-11 | 1996-11-14 | Applied Research Systems | Il-6 activity inhibitor |
| IL118474A (en) * | 1995-06-01 | 2001-08-08 | Sankyo Co | Benzimideol derivatives and pharmaceutical preparations containing them |
| TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| TW577875B (en) * | 1997-01-31 | 2004-03-01 | Shionogi & Co | Pyrrolidine derivatives with inhibitory activity for phospholipase A2 |
| JPH11124331A (ja) * | 1997-08-21 | 1999-05-11 | Takeda Chem Ind Ltd | 抗炎症剤 |
| US6331633B1 (en) * | 1998-05-08 | 2001-12-18 | Calyx Therapeutics Inc. | Heterocyclic analogs of diphenylethylene compounds |
| US6699896B1 (en) * | 1998-05-12 | 2004-03-02 | Wyeth | Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia |
| HUP0103082A3 (en) * | 1998-06-05 | 2002-12-28 | Astrazeneca Ab | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them |
| KR100613175B1 (ko) * | 1998-08-27 | 2006-08-17 | 오노 야꾸힝 고교 가부시키가이샤 | 카르복실산 유도체 및 그 유도체를 유효 성분으로서함유하는 약제 |
| PT1177187E (pt) | 1999-04-28 | 2007-09-03 | Sanofi Aventis Deutschland | Derivados ácidos de di-arilo como ligados do receptor ppar. |
| TWI284533B (en) * | 1999-05-24 | 2007-08-01 | Sankyo Co | Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant |
| WO2001002377A1 (en) | 1999-07-01 | 2001-01-11 | Geron Corporation | Telomerase inhibitors and methods of their use |
| AU778720B2 (en) * | 1999-08-23 | 2004-12-16 | Kyorin Pharmaceutical Co. Ltd. | Substituted benzylthiazolidine-2,4-dione derivatives |
| US6515003B1 (en) * | 1999-08-31 | 2003-02-04 | Maxia Pharmaceuticals, Inc. | Heterocyclic derivatives for the treatment of diabetes and other diseases |
| JP2001199888A (ja) * | 2000-01-24 | 2001-07-24 | Fujimoto Brothers:Kk | 糖尿病治療剤 |
| JP2001294537A (ja) * | 2000-02-10 | 2001-10-23 | Takeda Chem Ind Ltd | 併用医薬 |
| DE60115132T2 (de) | 2000-04-21 | 2006-07-06 | Pfizer Products Inc., Groton | Thyroid-Rezeptorliganden |
| US6680387B2 (en) * | 2000-04-24 | 2004-01-20 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
-
2003
- 2003-01-31 US US10/356,113 patent/US6794401B2/en not_active Expired - Lifetime
-
2004
- 2004-01-13 BR BRPI0406772A patent/BRPI0406772B1/pt not_active IP Right Cessation
- 2004-01-13 PT PT04701752T patent/PT1583529E/pt unknown
- 2004-01-13 MX MXPA05007684A patent/MXPA05007684A/es active IP Right Grant
- 2004-01-13 NZ NZ541328A patent/NZ541328A/en not_active IP Right Cessation
- 2004-01-13 SI SI200431804T patent/SI1583529T1/sl unknown
- 2004-01-13 ES ES04701752T patent/ES2374724T3/es not_active Expired - Lifetime
- 2004-01-13 AT AT04701752T patent/ATE532510T1/de active
- 2004-01-13 AU AU2004207449A patent/AU2004207449A1/en not_active Abandoned
- 2004-01-13 JP JP2006536536A patent/JP4833072B2/ja not_active Expired - Fee Related
- 2004-01-13 EP EP04701752A patent/EP1583529B9/en not_active Expired - Lifetime
- 2004-01-13 EA EA200501078A patent/EA200501078A1/ru unknown
- 2004-01-13 CA CA2513496A patent/CA2513496C/en not_active Expired - Fee Related
- 2004-01-13 DK DK04701752.0T patent/DK1583529T3/da active
- 2004-01-13 KR KR1020057013193A patent/KR101085315B1/ko not_active Expired - Fee Related
- 2004-01-13 WO PCT/US2004/000790 patent/WO2004066964A2/en not_active Ceased
- 2004-01-14 TW TW093100932A patent/TWI325420B/zh not_active IP Right Cessation
- 2004-09-21 US US10/947,047 patent/US20050096366A1/en not_active Abandoned
-
2005
- 2005-08-01 NO NO20053714A patent/NO330984B1/no not_active IP Right Cessation
- 2005-08-16 MA MA28444A patent/MA27658A1/fr unknown
-
2012
- 2012-02-09 CY CY20121100137T patent/CY1112673T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1583529T3 (da) | 2012-01-23 |
| KR101085315B1 (ko) | 2011-11-22 |
| ES2374724T3 (es) | 2012-02-21 |
| NZ541328A (en) | 2008-11-28 |
| EP1583529A2 (en) | 2005-10-12 |
| WO2004066964A2 (en) | 2004-08-12 |
| BRPI0406772A (pt) | 2005-12-27 |
| ATE532510T1 (de) | 2011-11-15 |
| NO330984B1 (no) | 2011-08-29 |
| TWI325420B (en) | 2010-06-01 |
| KR20050092764A (ko) | 2005-09-22 |
| WO2004066964A9 (en) | 2004-09-02 |
| JP4833072B2 (ja) | 2011-12-07 |
| WO2004066964A3 (en) | 2005-02-24 |
| TW200418792A (en) | 2004-10-01 |
| US6794401B2 (en) | 2004-09-21 |
| NO20053714L (no) | 2005-10-11 |
| MA27658A1 (fr) | 2005-12-01 |
| BRPI0406772B1 (pt) | 2016-08-23 |
| NO20053714D0 (no) | 2005-08-01 |
| JP2007501288A (ja) | 2007-01-25 |
| EP1583529A4 (en) | 2007-07-04 |
| PT1583529E (pt) | 2012-02-13 |
| SI1583529T1 (sl) | 2012-02-29 |
| EA200501078A1 (ru) | 2006-02-24 |
| CY1112673T1 (el) | 2016-02-10 |
| US20050096366A1 (en) | 2005-05-05 |
| CA2513496A1 (en) | 2004-08-12 |
| EP1583529B9 (en) | 2012-04-04 |
| AU2004207449A1 (en) | 2004-08-12 |
| EP1583529B1 (en) | 2011-11-09 |
| CA2513496C (en) | 2013-05-14 |
| US20040142991A1 (en) | 2004-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112673T1 (el) | Φαινοξυ αιθερες αμινοξεων | |
| AU2003281978A1 (en) | 2,5-diketopiperazines for the treatment of obesity | |
| ATE519501T1 (de) | Rekombinanter anti-cd40 antikörper und dessen anwendungen | |
| MY151032A (en) | Treatment of tnf? related disorders | |
| TW200509892A (en) | Novel aminobenzophenone compounds | |
| PL366619A1 (en) | Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders | |
| WO2006023844A3 (en) | Compositions and methods comprising proteinase activated receptor antagonists | |
| AU2000233235A1 (en) | Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase | |
| EP1625207A4 (en) | COMPOUNDS FOR THE TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISORDERS | |
| IL189452A0 (en) | Therapy with cd4 binding peptides and radiation | |
| WO2004002418A3 (en) | Compositions and methods comprising protein activated receptor antagonists | |
| SI1622939T1 (sl) | Akrivne variante il-18 vezavnega proteina in medicinske uporabe le-tega | |
| UA90698C2 (en) | Triazole substituted aminobenzophenone compounds | |
| EP2107071A3 (en) | Anti-EpCAM immunoglobulins | |
| WO2004099388A3 (en) | Cbl-b polypeptides, complexes and related methods | |
| WO2004078130A3 (en) | Posh interacting proteins and related methods | |
| WO2004089302A3 (en) | Posh polypeptides, complexes and related methods | |
| UA92013C2 (en) | Novel indoline compounds | |
| WO2004056762A3 (en) | Novel aminobenzophenone compounds | |
| TW200517125A (en) | Pharmaceutical composition for treatment of solid cancers | |
| IL152232A0 (en) | Promoter to il-18bp, its preparation and use | |
| WO2003101988A3 (en) | Compounds and compositions for the treatment of diabetes and diabetes-related disorders | |
| MXPA05003844A (es) | Compuestos con base de glucosa con afinidad para p-selectina. | |
| WO2004032856A3 (en) | Compounds | |
| WO2005018567A3 (en) | Compounds and compositions for the treatment of diabetes and diabetes-related disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |